CV-6209

• Description :

  CV-6209 is a potent antagonist of platelet activating factor (PAF) . CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats[1].

• UNSPSC :

  12352005

• Target :

  Platelet-activating Factor Receptor (PAFR)

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/cv-6209.html

• Concentration :

  10mM

• Purity :

  98.0

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC[N+]1=CC=CC=C1CN(C(C)=O)C(OCC(OC)COC(NCCCCCCCCCCCCCCCCCC)=O)=O.[Cl-]

• Molecular Formula :

  C34H60ClN3O6

• Molecular Weight :

  642.31

• References & Citations :

  [1]Terashita Z, et, al. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242 (1) :263-8.|[2]Munoz-Cano R, et, al. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study) . J Investig Allergol Clin Immunol. 2017;27 (3) :161-168.|[3]Fernande CA, et, al. Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther. 2015 Mar;352 (3) :541-51.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [100488-87-7]